Vertex Pharmaceuticals bags UK approval for ALYFTREK, a next-generation cystic fibrosis treatment

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor), a next-generation CFTR modulator treatment developed by Vertex Pharmaceuticals ... Read More